Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a report released on Tuesday, Benzinga reports. Other equities research analysts have also issued research reports about the company. Wells Fargo & Company upped their target price on Neurocrine Biosciences from $127.00 to […]